Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11440954 Optimized anti-TL1A antibodies

Overview Structured Data Issues Contributors Activity

Is a

Date Filed

April 30, 2020

Date of Patent

September 13, 2022

Patent Application Number

16863971

Patent Citations

US Patent 10221251 Sequence symmetric modified IGG4 bispecific antibodies

US Patent 10232017 Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides

US Patent 10316083 Signature of TL1A (TNFSF15) signaling pathway

US Patent 10322174 Neutralizing anti-TL1A monoclonal antibodies

US Patent 10526413 Bispecific antibodies specific for OX40

US Patent 10464981 Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules

US Patent 10689439 Optimized anti-TL1A antibodies

US Patent 10011644 Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof

US Patent 10138296 Antibodies that specifically bind to TL1A

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Primary Examiner

Bridget E Bunner

CPC Code

•••

Find more entities like US Patent 11440954 Optimized anti-TL1A antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool